Merck Says FDA Approves Ebola Zaire Vaccine Ervebo
December 20 2019 - 8:03AM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. (MRK) said the U.S. Food and Drug
Administration approved Ervebo for the prevention of disease caused
by Zaire ebolavirus in individuals 18 years and older.
Merck said it is working to initiate manufacturing of licensed
doses and expects these doses to start becoming available in about
the third quarter of 2020. The company said it is working closely
with the U.S. government; World Health Organization; UNICEF; and
Gavi, the Vaccine Alliance.
Merck said that, during this transition period, it is continuing
to work with its partners to ensure uninterrupted access to the
investigational Ebola Zaire vaccine, V920, in support of ongoing
international response efforts in the Democratic Republic of the
Congo and neighboring countries.
Merck said it also made submissions to African country national
regulatory authorities in collaboration with the African Vaccine
Regulatory Forum that will allow the vaccine to be registered in
African countries considered to be at-risk for Ebola outbreaks by
the WHO.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 20, 2019 07:48 ET (12:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
